ÂÜÀòÂÒÂ×

A recognized expert in genome editing technologies, TJ Cradick, PhD has developed nucleases, as well as genome editing and gene therapy reagents and methods for CRISPR/Cas nuclease, TAL Effector Nucleases (TALENs) and Zinc Finger Nucleases (ZFNs), both in his academic work at University of Iowa and the Georgia Institute of Technology, and in-industry at Sangamo Therapeutics (NASDAQ: SGMO). He has co-authored manuscripts on each of these nuclease technologies and on developing bioinformatics web tools including ZFN-Site, PROGNOS, SAPTA and COSMID. He also led the first work on the use of engineered nucleases as a therapeutic strategy for targeting Hepatitis B virus DNAs, and co-authored the first publication on the topic. He most recently served as the head of genome editing at CRISPR Therapeutics (NASDAQ: CRSP), and was previously a member of the faculty and director of the protein engineering facility at the Georgia Institute of Technology, where his research included developing assays for CRISPR/Cas9 specificity, which have been applied across a range of gene therapy targets.